LONDON, Aug. 10, 2016 /PRNewswire/ -- This report analyzes the current and future prospects of the viral conjunctivitis pipeline drugs market across major countries. Viral conjunctivitis is a highly contagious disease; however, not a single drug has been approved by the U.S. FDA to treat it. Hence, demand for these drugs for viral conjunctivitis is likely to increase after their expected launch.
The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides estimated market size in terms of US$ Mn for each drug for the period from expected launch to 2023, considering the macro and micro environmental factors. Growth rates for each drug within the market have been determined after a thorough analysis of current scenario, demographics, epidemiological study, future trends, competition with other pipeline drugs, and regulatory requirements.
The market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on the drug and geographic analysis. Based on pipeline drug, the market has been segmented into FST-100 and APD-209. Market size estimations involved in-depth study of both the drugs and product information. Additionally, market related factors such as product innovation, number of viral conjunctivitis patients in various countries, and expected launch date were taken into consideration while estimating the market size. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from expected launch to 2023.
Based on geography, the market has been analyzed for major countries: the U.S., the U.K., Germany, Australia, Japan, and Brazil. The market forecast for each of these countries has been provided for the period from expected launch in the country to 2023, along with their respective CAGRs for the forecast period from expected launch to 2023. The countries are selected based on ongoing clinical trial for FST-100 and APD-209.
A detailed qualitative analysis of factors responsible for driving and restraining the market and opportunities have been provided in the market overview section. This section of the report also provides epidemiological data and patent analysis of pipeline drugs, with a thorough analysis of the overall competitive scenario in the viral conjunctivitis pipeline drugs market.
A list of recommendations has been provided for new entrants to assist them in taking strategic initiatives to establish a strong presence in the market. The report also profiles major players in the market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The viral conjunctivitis pipeline drugs market is highly consolidated. Major companies profiled in this market report are Adenovir Pharma AB, Allergan plc, NanoViricides, Inc., Shire plc, NovaBay Pharmaceuticals, Inc., Novartis AG, Panoptes Pharma GES.M.B.H., and NicOx S.A.
The viral conjunctivitis pipeline drugs market has been segmented as follows:
Viral Conjunctivitis Pipeline Drugs Market, by Drug
Viral Conjunctivitis Pipeline Drugs Market, by Country
Download the full report: https://www.reportbuyer.com/product/4002254/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers